Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Isatuximab + Dexamethasone for t(11;14) Multiple Myeloma
NCT06115135Phase 2Recruiting
- Sponsor
- ONCOtherapeutics
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in multiple myeloma (MM), sponsored by ONCOtherapeutics. Started Jun 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06115135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115135.